There were 112 press releases posted in the last 24 hours and 437,640 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image